A Look At The Fair Value Of Stevanato Group S.p.A. (NYSE:STVN)
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $22
Express News | Stevanato Group Spa : BofA Global Research Cuts Price Objective to $24 From $28
Stevanato Group Will Introduce Its Large-Volume Vertiva 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan
Here's Why ClearBridge SMID Cap Growth Strategy Exited Stevanato (STVN)
SCHOTT Pharma, Gerresheimer, and Stevanato Form Alliance, Push RTU Solutions For Pharma Efficiency
Morgan Stanley Reaffirms Their Hold Rating on Stevanato Group (STVN)
Do Fundamentals Have Any Role To Play In Driving Stevanato Group S.p.A.'s (NYSE:STVN) Stock Up Recently?
Should You Hold Stevanato Group S.p.A. (STVN)?
S&P 500 Futures Steady In Premarket Trading; Credo Tech Group, Frontier Comms Parent Lag
Ambarella, Bill Holdings And Box Are Among Top 7 Mid Cap Gainers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
Stevanato Group to Present at Upcoming Investor Conferences
Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Pharvaris (PHVS) and Stevanato Group (STVN)
Multiple Factors Pulled Down Stevanato Group S.p.A. (STVN) Shares in Q2
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $22
Morgan Stanley analyst Drew Ranieri maintains $Stevanato Group(STVN.US)$ with a hold rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 38.1%
Morgan Stanley Remains a Hold on Stevanato Group (STVN)
Stevanato Group Navigates Q2 Challenges, Optimistic on Growth
Weak Statutory Earnings May Not Tell The Whole Story For Stevanato Group (NYSE:STVN)
Stevanato Group S.p.A. Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next